DIPLOMAT PHARMACY INC (DPLO) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:DPLO -
4
+0.01 (+0.25%)
4
0 (0%)
No Fundamental Analysis report for DPLO not available.
4
+0.01 (+0.25%)
Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)
Earnings (Next)
Inst Owners83.92%
Inst Owner Change0.04%
Ins Owners1.72%
Ins Owner Change0%
Market Cap304.00M
Revenue(TTM)5.21B
Net Income(TTM)-649.07M
Analysts56
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly Dividend0
Dividend Growth(5Y)0%
DP0%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.06 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.32 | ||
| P/tB | N/A | ||
| EV/EBITDA | -15.3 |
EPS(TTM)-0.54
EYN/A
EPS(NY)-0.62
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS68.5
BVpS1.72
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -55.83% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | -11.8% | ||
| PM (TTM) | -12.47% | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover4.48
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.55 | ||
| Quick Ratio | 0.36 | ||
| Altman-Z | 1.54 |
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-198.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-102178.26%
EPS Next Y-560%
EPS Next 2Y-263.7%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-1.53%
Revenue growth 3YN/A
Revenue growth 5Y18.64%
Sales Q2Q%-5.25%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A
DIPLOMAT PHARMACY INC / DPLO FAQ
What is the fundamental rating for DPLO stock?
ChartMill assigns a fundamental rating of 1 / 10 to DPLO.
What is the valuation status for DPLO stock?
ChartMill assigns a valuation rating of 1 / 10 to DIPLOMAT PHARMACY INC (DPLO). This can be considered as Overvalued.
How profitable is DIPLOMAT PHARMACY INC (DPLO) stock?
DIPLOMAT PHARMACY INC (DPLO) has a profitability rating of 1 / 10.
What is the expected EPS growth for DIPLOMAT PHARMACY INC (DPLO) stock?
The Earnings per Share (EPS) of DIPLOMAT PHARMACY INC (DPLO) is expected to decline by -560% in the next year.